The current ESLA market cap is 36.54M. The company's latest EPS is USD -0.2021 and P/E is -4.90.
Year End 30 June 2024 | 2021 | 2022 | 2024 |
---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 | 0 |
Operating Income | -249k | -1.57M | -7.31M |
Net Income | -248k | -996k | -7.31M |
Year End 30 June 2024 | 2021 | 2022 | 2024 |
---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 45.8M | 9.72M | 4.45M |
Total Liabilities | 1.62M | 2.65M | 181k |
Total Equity | -1.01M | -2.26M | 4.27M |
Market Cap | 36.54M |
Price to Earnings Ratio | -4.90 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 8.6 |
Price to Book Ratio | 8.38 |
Dividend Yield | - |
Shares Outstanding | 36.18M |
Average Volume (1 week) | 61.73k |
Average Volume (1 Month) | 108.79k |
52 Week Change | -1.94% |
52 Week High | 3.23 |
52 Week Low | 0.63 |
Spread (Intraday) | 0.42 (30.64%) |
Company Name | Estrella Immunopharma Inc |
Address |
108 w. 13th street wilmington, delaware 19801 |
Website | https:// |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions